Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy

C. Y. Cheah, Michael S. Hofman, M. Dickinson, A. Wirth, D Westerman, S. J. Harrison, Kate Burbury, M. Wolf, Elchanan H Januszewicz, K. Herbert, H Miles Prince, D A A Carney, David S. Ritchie, R. J. Hicks, John F. Seymour

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background:The usefulness of positron emission tomography with computed tomography (PET-CT) in the surveillance of patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission after primary therapy is not well studied.Methods:We performed a retrospective review of our database between 2002 and 2009 for patients with de novo DLBCL who underwent surveillance PET-CT after achieving complete metabolic response (CMR) following primary therapy.Results:Four-hundred and fifty scans were performed in 116 patients, with a median follow-up of 53 (range 8-133) months from completion of therapy. Thirteen patients (11%) relapsed: seven were suspected clinically and six were subclinical (all within first 18 months). The positive predictive value in patients with international prognostic index (IPI) <3 was 56% compared with 80% in patients with IPI≥3. Including indeterminate scans, PET-CT retained high sensitivity 95% and specificity 97% for relapse.Conclusion:Positron emission tomography with computed tomography is not useful in patients for the majority of patients with diffuse large B-cell lymphoma in CMR after primary therapy, with the possible exception of patients with baseline IPI ≥3 in the 18 months following completion of primary therapy. This issue could be addressed by a prospective clinical trial.

Original languageEnglish
Pages (from-to)312-317
Number of pages6
JournalBritish Journal of Cancer
Volume109
Issue number2
DOIs
Publication statusPublished - 23 Jul 2013
Externally publishedYes

Fingerprint Dive into the research topics of 'Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy'. Together they form a unique fingerprint.

Cite this